Protara Therapeutics Q4 net loss $17.3M; TARA-002 shows 68% CR in BCG-Unresponsive NMIBC

Protara Therapeutics, Inc.

Net loss Q4 2025: $17.3M ($0.37/share); FY2025: $57.4M ($1.34/share).
Cash $197.9M as of Dec 31, 2025; expects funding into 2028 after $86.3M December offering.
TARA-002 in BCG-Unresponsive NMIBC: 68.2% complete response at six months; no grade 3+ TRAEs.
FDA granted TARA-002 Breakthrough Therapy and Fast Track designations for lymphatic malformations.
Expects to complete BCG-Unresponsive cohort enrollment in 2H 2026; initiate ADVANCED-3 trial in 2H 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Protara Therapeutics, Inc. reported financial results for the fourth quarter of 2025.

Period: the fourth quarter of 2025
Result: reported results

Exact text from the filing

Research and development expenses for the fourth quarter of 2025 increased to $13.1 million from $9.5 million for the prior year period

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Protara Therapeutics, Inc. reported financial results for the full year ended December 31, 2025.

Period: the full year ended December 31, 2025
Result: reported results

Exact text from the filing

and for the full year increased to $42.6 million compared to $31.7 million for 2024

View on SEC.gov

Browse all earnings releases →

Protara Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-025432

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.